

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/281887439>

Identification of antimicrobial compounds produced by pseudomonas aeruginosa Ns3symbionascidian phallusia Julinea

Article in International Journal of ChemTech Research · January 2015

CITATIONS

5

READS

679

4 authors, including:



Rina Moge

State University of Papua

12 PUBLICATIONS 10 CITATIONS

[SEE PROFILE](#)



Tri Ardyati

Brawijaya University

67 PUBLICATIONS 173 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



microbiology [View project](#)



Detection of class 1 integron-associated gene cassettes and tetracycline resistance genes in Escherichia coli isolated from ready to eat vegetables [View project](#)



Identification of antimicrobial compounds produced by *Pseudomonas aeruginosa* NS3symbionascidian *Phallusia julinea*

Rina A. Moge^{1,3*}, Suharjono², Tri Ardyati², Setijono Samino²

¹Biology Doctoral Program, Faculty of Sciences, Brawijaya University

²Department of Biology, Faculty of Sciences Brawijaya University, Indonesia

³Department of Biology, Faculty of Mathematics and Natural Sciences, The State University of Papua, Indonesia

Abstract: Marine organisms have developed exquisitely complex biological mechanisms and they are known as source producing bioactive compound. The objective of this study is to test cell-free *P. aeruginosa* NS3 on pathogenic microbes and to identify antimicrobial compounds in supernatants. The method bacterial culture of *P. aeruginosa* NS3 was harvested on 72hour at the exponential growth phase and it was then centrifuged. Cell-free supernatants were tested on pathogenic microbes using disc diffusion method, the pigment components were characterized by UV-vis and weightmolecules of bioactive secondary metabolites was identified using LC-MS/MS. The result showed that cell-free supernatants of *P. Aeruginosa* NS3 could inhibit pathogenic microbes with MRSA inhibition zone of 8 ± 0.5 mm, *S. aureus* 25 ± 2.7 mm, EPEC30 ± 5.2 mm and *Candida albicans* 22 ± 3.5 mm. The minimum inhibitory concentration ranged from 31.25 to 500 ppm. The *P. aeruginosa*NS3 bacteria produced phenazine antimicrobial compounds with pyocyanin component (211m/z), 1-hydroxyphenazine (196m/z), phenazine-1-carboxamide (179m/z) and phenazine-1-carboxylic acid (155 m/z).*P. aeruginosa*NS3 bacteria producedphenazine-containing compound that has the ability to inhibit pathogenic microbes. The greatest inhibitors were EPEC, *S. aureus*, *C. albicans* and MRSA. It is necessary to conduct further research which uses their bioactive compounds in pharmaceuticals such as antiviral, anticancer, and anti-inflammatory.

Key words: antimicrobial activity, bioactive compounds, phenazine, free-cell supernatants,*P. aeruginosa*NS3.

Introduction

Recently, there have been many microbes resistant to antibiotics and it is necessary to find new antibiotics that can inhibit resistant bacteria and can meet the elements of producing an antibiotic. Marine microbes are a potential source of bioactive compounds that have become a concern and have been used as antimicrobials, anticancer, anti-inflammatory, antiviral, antinematoda, and antiprotozoa¹. The bacteria may live in the water free and there are also bacteria which are associated with a variety of marine organisms such as ascidians. The mutual association of bacteria and ascidians will produce a variety of bioactive compounds such as antimicrobial compounds. Through the production of antimicrobial compounds, bacteria can adapt to the environment and defend themselves from other bacteria and their host^{2,3,4}.

In the previous research, *Pseudomonas aeruginosa* NS3 bacteria which had been associated with *Phallusia julinea* ascidian had been isolated. These bacteria which had a potential to produce bioactive compounds belong to the Gamma Proteobacteria class with these characteristics: Gram-negative, rod-shaped, motile, forming smooth spherical colonies with greenish fluorescent color, wide spread in the environment. These bacteria produce pyocyanin pigment which is soluble in water, chloroform and n-butanol^{5,6,7,8}. The objective of this research was to test the cell-free supernatants of *P. aeruginosa* NS3 on pathogenic microbes and to identify antimicrobial compounds in the supernatants.

Material and Methods

Growth medium

P. aeruginosa NS3 was isolated from the *Phallusia julinea* ascidian which was found in Doreri Gulf, Manokwari, West Papua. The isolates were cultured in slant sea water complete (SWC) media with the composition of 5g/L bacto-peptone, 1 g/L yeast extract and 3 ml/L glycerol and 15 g bacto agar⁹. Bacterial colonies were incubated on media SWC slant for 24 hours at the temperature of 30 °C and used to measure the biomass density.

Biomass density measurement

Bacterial biomass was measured based on the *P. aeruginosa* NS3 growth-curve using turbidimetric method. One loop of *P. aeruginosa* cultured into a 250-ml Erlenmeyer containing 150 mL SWC broth, then it was incubated in a shaker incubator at 30 °C, pH 7, with the agitation of 120 rpm for 24 hours and the optical density (OD) was measured on 0, 1, 2, 4, 6, 8, 10, 14, 18, 24, 36, 48, 58, 72, and 92 hours. The isolates growth was measured using a spectrophotometer (Shimadzu 1240) at a wavelength of 620 nm. The growth curve showed the relationship between the incubation time and the biomass density. Culture isolates used to test the antimicrobial were the ones which had reached the highest exponential growth phase.

P. aeruginosa NS3 antimicrobial activity test

Culture of *P. aeruginosa* NS3 were centrifuged at a speed of 10,000 rpm, at 4 °C for 15 minutes to separate the supernatants and the cell mass. The supernatants were filtered with a 0.22 µm milipore syringe filter. The cell-free supernatant was used to test the antimicrobial on methicillin-resistant of *Staphylococcus aureus* (MRSA), *S. aureus*, EPEC and *C. albicans* using disc diffusion method. Culture of microbes 0.1 mL was spread on the SWC and Potato Dextrose Agar media. Disc paper Ø 5 mm which had been soaked in 50 µL of bacterial culture supernatant was placed on the surface of the test medium. Cultures in a Petri dish were incubated for 24 hours at 30 °C, then, a clear zone formed was observed and its diameter was measured¹⁰.

Determination of minimum inhibitory concentration of *P. aeruginosa* NS3 supernatant

The minimum inhibitory concentration (MIC) determination was done by dilution serial of *P. aeruginosa* NS3 cell-free supernatant. As a result, serial concentration was obtained (2000; 1000; 500; 250; 125; 62.5; 31.5) ppm. Tube number one until seven was filled with 0.1 mL pathogenic bacterial cultures. All tubes were homogenized for 2 minutes and incubated for 24 hours at the temperature of 30 °C. Antimicrobial activity would be noticed if there was a decrease in culture optical density measured by a spectrophotometer at the wavelength of 620 nm. Antimicrobial supernatant MIC value was obtained at the highest level of dilution which could inhibit pathogenic microbes¹¹.

Analysis of *P. aeruginosa* NS3 antimicrobial compounds

Supernatant of bacterial isolates were subsequently precipitated by the addition of chloroform (2: 1), homogenized for 1 minute and 0.1 N HCl was later added until the color changed¹². These pigments are characterized by UV-visible spectrophotometer (UV-1600) with the absorbance of 340 nm and identified by liquid chromatography electro spray ionization-mass spectrometry analysis (LC-MS / MS) to determine the secondary metabolites molecular weight. Instrument used was triple quadrupole MS instrument (Thermo Scientific, USA). Detector used was a 3200 QTRAP mass spectrometer, Phenomenex C18 column (50 mm x 2mm) with flow rate of 0.2 ml/min, analysis time of 5 minutes, injection volume of 5 µL, column temperature

of 25 °C, gradient elution flow of 10% eluen B. Mobile phase A consisted of a mixture of distilled water and glacial acetic acid, mobile phase B: acetonitrile¹³.

Results and Discussion

*P. aeruginosa*NS3 growth patterns were determined based on the biomass density with turbidimetric method and directly counting the cells under a microscope using haemocytometer. *P. aeruginosa*NS3 bacteria required nutrition containing mineral and suitable environmental conditions for optimum growth. In this study, the observations of growth in Figure 1 showed the exponential phase occurred on 6 to 72 hours and later experienced the decrease in number of cells or the death phase.




Figure 1. Growth curve of *P. aeruginosa* NS3

At the growth the exponential phase antimicrobial compound has been formed so that the biomass harvest was done at the end of the exponential phase¹⁴. *P. aeruginosa*NS3 bacterial cultures were harvested on 72nd hours and then separated using a centrifuge for 15 minutes at the speed of 10.000 rpm at the temperature of 4 °C. The supernatant was used to the antimicrobial activity assay.

Antimicrobial compound activity assay used the disc diffusion method. The results showed that *P. aeruginosa*NS3 supernatant could inhibit pathogenic microbes Table 1. Activity test showed different responses of pathogenic microbes towards the minimum inhibitory concentration. At the concentration of 500 ppm, the antimicrobial substance was able to inhibit the growth of Gram positive bacteria that was MRSA and *S. aureus*, whereas at the concentration of 250 ppm, it could inhibit the growth of EPEC and at 31.25 ppm, it could inhibit the growth of *C. albicans*.

Table 1. Diameters of the zones of inhibition (mm) and the MIC by cell-free supernatant *Pseudomonas aeruginosa* NS3

Microbial pathogens	Diameters fo inhibition Zone (mm)*	MIC (ppm)
MRSA	8±0.5	500
<i>S. aureus</i>	25±2.7	500
EPEC	30±5.2	250
<i>C. albicans</i>	22±3.5	31.25

*) The average value and standard deviation with triplicate measurement for each value

From MIC test results, it was found that the greater concentration used has greater the inhibitory activity. The higher of the concentration of an antimicrobial used, the more quickly the microbes killed¹⁵. This is not recommended for a medical treatment because it can cause resistance. The minimum inhibitory concentration required by MRSA and *S. aureus* was higher because the bacteria have thicker cell wall compared to others.

The identification results of active compounds produced by *P. aeruginosa*NS3 bacterium showed that the bacterium produced phenazine. It is obvious that when the chloroform was added, the supernatant changed its color to bluish and when 0.1 N HCL was added, it changed to reddish. The supernatant was analyzed using UV-visible spectrophotometer to confirm the presence of the phenazine by generating absorption at the wavelength of 279, -343, -369, -372 nm Figure 2.




Figure 2. UV absorption spectra of *P. aeruginosa* NS3 showing λ_{\max} 340nm

The supernatant was analyzed by LC-MS / MS to determine the molecular weight of the components Figure 3. Phenazine components produced by *P. aeruginosa* NS3 were pyocyanin (211m/z), 1-hydroxyphenazine (196m/z), phenazine-1-carboxamide (179m/z) and phenazine-1-carboxylic acid (155m/z).




Figure 3. LC-MS/MS analyses of phenazine compounds produced by *P. aeruginosa* NS3

The phenazine contained heterocyclic nitrogen and possessed the activity of antimicrobial, antitumor, and antiparasitic^{16,17}. Some studies suggest that phenazine efficiently inhibits bacteria and fungi^{8,18,19}. The phenazine was produced during the stationary phase⁵. Active mechanism of the phenazine compound was by damaging the cell membrane, inhibiting the synthesis of nucleic acids and proteins⁷.

Conclusion

P. aeruginosa NS3 bacteria which were isolated from *P. julinea* ascidian found in Doreri Gulf, Manokwari, West Papua had antimicrobial activity. The antimicrobial substance produced by *P. aeruginosa* NS3 could inhibit pathogenic microbes MRSA, *S. aureus*, EPEC and *C. albicans*.

The antimicrobial compound from *P. aeruginosa* NS3 bacteria was phenazine consist of pyocyanin, 1-hydroxyphenazine, phenazine-1-carboxamide and phenazine-1-carboxylic acid.

References

1. Penesyan A, Kjelleberg S, Egan, S. "Development of novel drugs from marine surface associated microorganisms". *Marine Drugs*, 2010, 8:438-459.
2. Mearns-Spragg A, Bregu M, Boyd KG, Burgess JG. "Cross-species induction and enhancement of antimicrobial activity produced by epibiotic bacteria from marine algae and invertebrates, after exposure to terrestrial bacteria". *Letter Applied Microbiology*, 1998, 27:142-146.
3. Armstrong E, Liming Y, Kenneth GB, Phillip CW, Grant B. "The symbiotic role of marine on living surfaces". *Hydrobiologia*, 2001, 461:37-40.

4. Hardoim CCP, Costa R, Aroujo FV, Hajdu E, Peixoto R., Lins U, Rosado AS, van Elsas JD. "Diversity bacteria in the marine sponge *Aplysina fulva* in Brazilian coastal waters". Applied and Environmental microbiology, 2009, 75(10):3331-3343.
5. Mavrodi DV, Bonsall RF, Delaney SM, Soule MJ, Phillips G, Thomashow LS. "Functional analysis of genes for biosynthesis of pyocyanin and phenazine-1-carboxamide from *Pseudomonas aeruginosa* PAO1". Journal of Bacteriology, 2001, 183(21):6454-6465.
6. Mandryk MN, Kolomiets EL, Dey ES. "Characterization of antimicrobial compounds produced by *Pseudomonas aurantiaca* S-1". Polish Journal of Microbiology, 2007, 56(4):245-250.
7. Isnansetyo A, Kamei Y. "Bioactive substances produced by marine isolates of *Pseudomonas*". J Ind Microbiol Biotechnol, 2009, 36:1239-1248.
8. Zhou T, Chen D, Li C, Sun Q, Li L, Liu F, Shen Q, Shen B. "Isolation and characterization of *Pseudomonas brassicacearum* J12 as an antagonist against *Raistonia solanacearum* and identification of its antimicrobial components". Microbiology Research, 2012, 167:388-394.
9. Bahgat M. "Diversity of bacterial communities in contrasting aquatic environments: Lake Timsah, Egypt". Microbiology Insights, 2011, 4:11-19.
10. Romanenk, LA, Uchino M, Kalinovskaya NI, Mikhailov VV. "Isolation, phylogenetic analysis and screening of marine mollusc-associated bacteria for antimicrobial, hemolytic and surface activities". Microbiological Research, 2008, 163:633-644.
11. Rollins D, Joseph S. BSCI 424 Streaking Technique Retrieved. University of Maryland. 2000.
12. Karpagam SA, Sudhakar T, Lakshmi pathy M. "Microbicidal response of pyocyanin produced by *P. aeruginosa* toward clinical isolates of fungi". International Journal of Pharmacy and Pharmaceutical Sciences, 2013, 5(3):870-873.
13. Usher LR, Lawson RA, Geary I, Taylor CJ, Bingle CD, Taylor GW, Whyte MKB. "Induction of neutrophil apoptosis by the *Pseudomonas aeruginosa* exotoxin pyocyanin: a potential mechanism at persistent infection". The Journal of Immunology, 2002, 168:1861-1868.
14. Pratiwi ST. "Mikrobiologi Farmasi", Erlangga Publisher. Jakarta. 2008, 237.
15. Pelczar MJ, Chan ECS. "Elements of Microbiology". Indonesia University. Publisher Jakarta, 2009, 443.
16. Pierson III LS, Pierson EA. "Metabolism and function of phenazines in bacteria impacts on the behavior of bacterium in the environment and biotechnological processes". App. Microbiol. Biotechnol, 2010, 86:1659-1670
17. Cardozo VF, Oliveira AG, Nishio EK, Perugini MRE, Andrade CGTJ, Silveira WD, Duran N, Andrade G, Kobayashi RKT, Nakato G. "Antibacterial activity of extracellular compounds produced by a *Pseudomonas* strain against methicillin-resistant *Staphylococcus aureus* (MRSA) strains". Annals of clinical microbiology and antimicrobials, 2013, 12(12):1-8.
18. Charyulu EM, Sekaran G, Rajakumar GS, Gnanamani A. "Antimicrobial activity of secondary metabolite from marine isolate, *Pseudomonas* sp. against Gram positive and negative bacteria including MRSA". Indian Journal of Experimental Biology, 2009, 47:964-968.
19. El-Shouny WA, Al-Baudari ARH, Hamza WT. "Antimicrobial activity of pyocyanin produced by *Pseudomonas aeruginosa* isolate from surgical wound infection". International journal of pharmacy and medical science, 2011, 1(1):01-107.
